Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Joseph OlivetoPresident and CEO | Milestone PharmaceuticalsMIST | Open-market sale10b5-1 plan | 04/16 | 04/20 | 36,500 sh | $2.26 | $82,490 | −7.6% |
Milestone PharmaceuticalsMIST | Open-market sale | 25/12/15–01/26 | 01/28 | 167,577 sh2 trades | $2.24avg. | $375,314.67 | −25.8% | |
Milestone PharmaceuticalsMIST | Open-market sale | 25/12/15–01/26 | 01/28 | 64,746 sh2 trades | $2.25avg. | $145,850.52 | −24.0% | |
Milestone PharmaceuticalsMIST | Open-market sale | 25/12/15–01/26 | 01/28 | 70,252 sh2 trades | $2.25avg. | $158,209.09 | −41.3% | |
Milestone PharmaceuticalsMIST | Open-market sale | 25/12/15–01/26 | 01/28 | 70,252 sh2 trades | $2.25avg. | $158,209.09 | −38.3% | |
Milestone PharmaceuticalsMIST | Open-market sale | 25/12/15–01/26 | 01/28 | 70,252 sh2 trades | $2.25avg. | $158,209.09 | −58.5% | |
Milestone PharmaceuticalsMIST | Open-market sale10b5-1 plan | 01/07–01/08 | 01/09 | 43,500 sh2 trades | $2.25avg. | $97,875 | −12.5% |